Aisling Capital Management’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.96M Hold
325,000
– – 0.99% 8
2026
Q2
$2.15M Hold
325,000
– – 0.46% 11
2026
Q1
$2.35M Buy
+325,000
New +$2.62M 0.49% 9

Other funds holding EPRX

Aisling Capital Management's EPRX Position: Q3 2026 in Review

Aisling Capital Management held its Eupraxia Pharmaceuticals (EPRX) position steady in Q3 2026 at 325,000 shares worth $2.96M. The position accounts for 0.99% of the portfolio, ranked #8.

Aisling Capital Management first reported a position in EPRX in Q1 2026 and has held it in 3 quarters since. 70 funds tracked by Wall St. Rank hold EPRX as of Q3 2026.

  • Aisling Capital Management held 325,000 shares of Eupraxia Pharmaceuticals worth $2.96M as of Q3 2026.
  • Aisling Capital Management left its Eupraxia Pharmaceuticals share count unchanged in Q3 2026.
  • Eupraxia Pharmaceuticals made up 0.99% of Aisling Capital Management's portfolio in Q3 2026, its #8 holding.
  • Aisling Capital Management first reported a position in Eupraxia Pharmaceuticals in Q1 2026 and has held it in 3 quarters since.
  • 70 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q3 2026.

Based on Aisling Capital Management's 13F filing for Q3 2026, filed 12 Nov 2026.